Standard Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Standard Investments’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-118,364	Closed	-$7M	–	110
2015 Q2	$7M	Buy	+118,364	New	+$7.3M	0.4%	30
2015 Q1	–	Sell	-33,928	Closed	-$1.95M	–	140
2014 Q4	$1.95M	Hold	33,928	–	–	0.1%	98
2014 Q3	$1.82M	Hold	33,928	–	–	0.1%	116
2014 Q2	$1.78M	Hold	33,928	–	–	0.11%	94
2014 Q1	$1.79M	Buy	+33,928	New	+$1.57M	0.17%	88

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Standard Investments's TEVA Position: Q3 2015 in Review

Standard Investments sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 118,364 shares — an estimated $7M sold.

Standard Investments first reported a position in TEVA in Q1 2014 and held it in 5 quarters. The position peaked at $7M in Q2 2015. 823 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Standard Investments reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Standard Investments sold 118,364 Teva Pharmaceuticals shares in Q3 2015, an estimated $7M.
Standard Investments first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Standard Investments's Teva Pharmaceuticals position peaked at $7M in Q2 2015.
823 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Standard Investments's 13F filing for Q3 2015, filed 16 Nov 2015.